PD-1 Inhibition Enhances Blinatumomab Response in a UCB/PDX Model of Relapsed Pediatric B-Cell Acute Lymphoblastic Leukemia

PD-1 Inhibition Enhances Blinatumomab Response in a UCB/PDX Model of Relapsed Pediatric B-Cell Acute Lymphoblastic Leukemia

Immune therapies such as blinatumomab, CD19-directed bispecific CD3 T-cell Engager (BiTE), have resulted in significant improvements in outcomes for relapsed B-cell acute lymphoblastic leukemia (B-ALL). However, up to half of blinatumomab treated patients do not respond completely or relapse after t...

Full description

Bibliographic Details
Main Authors:	Mark Wunderlich, Nicole Manning, Christina Sexton, Eric O’Brien, Luke Byerly, Cody Stillwell, John P. Perentesis, James C. Mulloy, Benjamin Mizukawa
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2021-04-01
Series:	Frontiers in Oncology
Subjects:	patient derived xenograft blinatumomab pembrolizumab B-ALL humanized mice immune checkpoint inhibition
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2021.642466/full

Similar Items

Blinatumomab in the Treatment of Acute Lymphoblastic Leukemia: Russian Multicenter Clinical Trial
by: SN Bondarenko, et al.
Published: (2019-03-01)

Clinical use of blinatumomab for B-cell acute lymphoblastic leukemia in adults
by: Lee KJ, et al.
Published: (2016-08-01)

Recent advances on blinatumomab for acute lymphoblastic leukemia
by: Juanjuan Zhao, et al.
Published: (2019-11-01)

Frontline Blinatumomab in Older Adults with Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia
by: Sandrine Niyongere, et al.
Published: (2020-06-01)

Antigen-based immunotherapy for the treatment of acute lymphoblastic leukemia: the emerging role of blinatumomab
by: Litzow MR
Published: (2014-04-01)

Immunotargeting relapsed or refractory precursor B-cell acute lymphoblastic leukemia – role of blinatumomab
by: Queudeville M, et al.
Published: (2017-07-01)

Blinatumomab-associated vasculitis
by: MeiQi May Liau, MBChB, MRCP (UK), M.Med, et al.
Published: (2017-09-01)

Complete remission in refractory acute lymphoblastic leukemia using blinatumomab after failure of response to CD‐19 chimeric antigen receptor T‐cell therapy
by: Francesco Paolo Tambaro, et al.
Published: (2020-09-01)

Potential for bispecific T-cell engagers: role of blinatumomab in acute lymphoblastic leukemia
by: Le Jeune C, et al.
Published: (2016-02-01)

Feasible outcome of blinatumomab followed by allogeneic hematopoietic cell transplantation for adults with Philadelphia chromosome‐negative acute lymphoblastic leukemia in first salvage
by: Jae‐Ho Yoon, et al.
Published: (2019-12-01)

Impact of blinatumomab on patient outcomes in relapsed/refractory acute lymphoblastic leukemia: evidence to date
by: Hathaway L, et al.
Published: (2018-10-01)

Improved chemotherapy modeling with RAG-based immune deficient mice.
by: Mark Wunderlich, et al.
Published: (2019-01-01)

Blinatumomab as first salvage versus second or later salvage in adults with relapsed/refractory B‐cell precursor acute lymphoblastic leukemia: Results of a pooled analysis
by: Max S. Topp, et al.
Published: (2021-04-01)

Blinatumomab for the Treatment of Adult B-Cell Acute Lymphoblastic Leukemia: Toward a New Era of Targeted Immunotherapy
by: Franquiz MJ, et al.
Published: (2020-02-01)

Changes in clinical laboratory parameters and pharmacodynamic markers in response to blinatumomab treatment of patients with relapsed/refractory ALL
by: Virginie Nägele, et al.
Published: (2017-05-01)

Evaluating Blinatumomab for the Treatment of Relapsed/Refractory ALL: Design, Development, and Place in Therapy
by: Sigmund AM, et al.
Published: (2020-11-01)

Case Report: Targeting 2 Antigens as a Promising Strategy in Mixed Phenotype Acute Leukemia: Combination of Blinatumomab With Gemtuzumab Ozogamicin in an Infant With a KMT2A-Rearranged Leukemia
by: Benoît Brethon, et al.
Published: (2021-02-01)

Blinatumomab-induced T cell activation at single cell transcriptome resolution
by: Yi Huo, et al.
Published: (2021-03-01)

Management of adverse effects of new monoclonal antibody treatments in acute lymphoblastic leukemia
by: Diego Conde-Royo, et al.
Published: (2020-10-01)

CD19 CAR-T cell therapy for relapsed/refractory acute lymphoblastic leukemia: factors affecting toxicities and long-term efficacies
by: Li-Na Zhang, et al.
Published: (2018-03-01)

PDX models reflect the proteome landscape of pediatric acute lymphoblastic leukemia but divert in select pathways
by: Anuli C. Uzozie, et al.
Published: (2021-03-01)

Treatment of Adult Patients with Relapsed/Refractory B-Cell Philadelphia-Negative Acute Lymphoblastic Leukemia
by: Enrico Maffini, et al.
Published: (2019-05-01)

Molecular remission after combination therapy with blinatumomab and ponatinib with relapsed/refractory Philadelphia chromosome-positive acute lymphocytic leukemia: two case reports
by: Junichiro Yuda, et al.
Published: (2021-03-01)

Have CD19-directed immunotherapy and haploidentical hematopoietic cell transplantation transformed pediatric B-cell acute lymphoblastic leukemia into a chronic disease?
by: Holly Pariury, et al.
Published: (2021-01-01)

Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions
by: Bachar Samra, et al.
Published: (2020-06-01)

A retrospective examination of the US Food and Drug Administration’s clinical pharmacology reviews of oncology biologics for potential use of therapeutic drug monitoring
by: Fleisher B, et al.
Published: (2017-12-01)

Novel Immunotherapy Agents for Acute Lymphoblastic Leukaemia
by: David Pesántez, et al.
Published: (2017-08-01)

Recent updates for antibody therapy for acute lymphoblastic leukemia
by: Le Li, et al.
Published: (2020-11-01)

Bispecific Antibodies in Clinical Practice and Clinical Trials (Literature Review)
by: ON Solopova, et al.
Published: (2019-03-01)

Diagnostics and treatment challenges of Ph-like acute lymphoblastic leukemia: a description of 3 clinical cases
by: K I ZARUBINA, et al.
Published: (2018-07-01)

PDX models of human lung squamous cell carcinoma: consideration of factors in preclinical and co-clinical applications
by: Hae-Yun Jung, et al.
Published: (2020-08-01)

Establishment and Characterization of Humanized Mouse NPC-PDX Model for Testing Immunotherapy
by: Wai Nam Liu, et al.
Published: (2020-04-01)

Generation of stable PDX derived cell lines using conditional reprogramming
by: Alexandra Borodovsky, et al.
Published: (2017-12-01)

Development of a Patient-Derived Xenograft (PDX) of Breast Cancer Bone Metastasis in a Zebrafish Model
by: Laura Mercatali, et al.
Published: (2016-08-01)

Machine-learning aided in situ drug sensitivity screening predicts treatment outcomes in ovarian PDX tumors
by: Ahn, S., et al.
Published: (2022)

Factors that influence response classifications in chemotherapy treated patient-derived xenografts (PDX)
by: Joan E. Malcolm, et al.
Published: (2019-03-01)

TOXICITY AND EFFICACY OF TYROSINE KINASE INHIBITORS IN COMBINATION WITH CHEMOTHERAPY IN PATIENT WITH RESISTANT Ph-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (CASE REPORT AND LITERATURE REVIEW)
by: K. I. Zarubina, et al.
Published: (2017-10-01)

Comparative study on contrast enhancement of Magnevist and Magnevist-loaded nanoparticles in pancreatic cancer PDX model monitored by MRI
by: Kevin Affram, et al.
Published: (2020-05-01)

Clinical and pharmacologic aspects of blinatumomab in the treatment of B-cell acute lymphoblastic leukemia
by: Portell CA, et al.
Published: (2013-04-01)

Patient-derived xenograft (PDX) models of colorectal carcinoma (CRC) as a platform for chemosensitivity and biomarker analysis in personalized medicine
by: Maria Rivera, et al.
Published: (2021-01-01)